ArticleCancers2024
Changes in the Incidence and Human Papillomavirus-Positive Portion of Oropharyngeal Squamous Cell Carcinoma in Hong Kong.
Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Systematic review of artificial intelligence and radiomics for preoperative prediction of extranodal extension and lymph node metastasis in oropharyngeal cancer.Frontiers in oncology · 2025Pooled it
- Cost-effectiveness and health impact of gender-neutral and single-dose HPV vaccination in Hong Kong: a modeling analysis.The Lancet regional health. Western Pacific · 2026Article
- PREVALENCE, CHARACTERISTICS AND TREATMENT OUTCOMES OF HPV POSITIVE OROPHARYNGEAL CARCINOMA IN AFRICA: A SYSTEMATIC REVIEW AND META-ANALYaSIS.Annals of Ibadan postgraduate medicine · 2026Article
- Epidemiological Trends in the Characterization of Human Papillomavirus Virus-Related Oropharyngeal Cancer: A Global Perspective.Current oncology reports · 2025Review
- HPV associated oropharyngeal cancer in eastern China over the last 7 years: is the incidence in chinese truly exceptionally low?BMC public health · 2025Article
- Study on the detection rate, genetic polymorphism, viral load, persistent infection capacity, and pathogenicity of human papillomavirus type 33.Virology journal · 2025Article
- Changes in risk habits and influencing factors in the Taiwan oral cancer screening program.PloS one · 2025Article
- Robotic Surgery for Head and Neck Tumors: What are the Current Applications?Current oncology reports · 2024Review
- Understanding the tumor microenvironment for personalized immunotherapy in early-onset head and neck squamous cell carcinoma.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
Abstract
The incidence of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is rising in the West, but little is known in Asia. This study elucidated changes in the incidence and HPV-positive portion of OPSCC in Hong Kong. Data from population-based cancer registry were used to analyze the incidence of OPSCC in association with other head and neck cancers. Archived tumor tissues were tested for HPV. From 1986 to 2020, there was a marked decrease in the incidence of nasopharyngeal and laryngeal cancers, but a persistent increase in OPSCC from 36 cases in 1986 to 116 cases in 2020. The average positive rate for high-risk HPV was 36.1% (112/310) among OPSCC diagnosed in 2010-2020. The HPV-positive rate in recent years was significantly higher than earlier cases (tonsil SCC: 64.7% (55/85) in 2016-2020 vs. 40.4% (19/47) in 2010-2015,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.